H. Lundbeck A/S (HLBBF)
HLBBF Stock Price Chart
Explore H. Lundbeck A/S interactive price chart. Choose custom timeframes to analyze HLBBF price movements and trends.
HLBBF Company Profile
Discover essential business fundamentals and corporate details for H. Lundbeck A/S (HLBBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
13 Jul 2022
Employees
5.71K
Website
https://www.lundbeck.comCEO
Charl van Zyl
Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
HLBBF Financial Timeline
Browse a chronological timeline of H. Lundbeck A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
Revenue estimate is $6.13B.
Earnings released on 13 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.15 by +1.80%, while revenue for the quarter reached $950.25M , missing expectations by -84.34%.
Earnings released on 13 May 2025
EPS came in at $0.17 surpassing the estimated $0.13 by +31.77%, while revenue for the quarter reached $917.67M , missing expectations by -84.63%.
Earnings released on 5 Feb 2025
EPS came in at $0.08 surpassing the estimated $0.06 by +40.65%, while revenue for the quarter reached $766.87M , missing expectations by -86.82%.
Dividend declared on 5 Feb 2025
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 31 Mar 2025.
Earnings released on 13 Nov 2024
EPS came in at $0.12 surpassing the estimated $0.11 by +5.79%, while revenue for the quarter reached $841.94M , beating expectations by +2.55%.
Earnings released on 20 Aug 2024
EPS came in at $0.11 falling short of the estimated $0.12 by -4.12%, while revenue for the quarter reached $788.92M , beating expectations by +4.00%.
Earnings released on 15 May 2024
EPS came in at $0.15 surpassing the estimated $0.12 by +26.17%, while revenue for the quarter reached $759.36M , beating expectations by +2.26%.
Earnings released on 20 Mar 2024
EPS came in at $0.02 falling short of the estimated $0.03 by -33.61%, while revenue for the quarter reached $734.60M , missing expectations by -3.06%.
Dividend declared on 7 Feb 2024
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 25 Mar 2024.
Earnings released on 30 Sept 2023
EPS came in at $0.10 surpassing the estimated $0.08 by +14.18%, while revenue for the quarter reached $698.73M , missing expectations by -2.53%.
Earnings released on 30 Jun 2023
EPS came in at $0.09 surpassing the estimated $0.08 by +13.78%, while revenue for the quarter reached $721.40M , beating expectations by +1.78%.
Earnings released on 31 Mar 2023
EPS came in at $0.13 surpassing the estimated $0.09 by +37.56%, while revenue for the quarter reached $735.36M , beating expectations by +4.32%.
Dividend declared on 8 Feb 2023
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 24 Mar 2023.
Earnings released on 7 Feb 2023
EPS came in at $0.61 surpassing the estimated $0.46 by +32.61%, while revenue for the quarter reached $675.97M , beating expectations by +3.25%.
Earnings released on 9 Nov 2022
EPS came in at $0.96 surpassing the estimated $0.72 by +33.33%, while revenue for the quarter reached $618.47M , beating expectations by +4.41%.
Earnings released on 17 Aug 2022
EPS came in at $0.71 surpassing the estimated $0.70 by +1.43%, while revenue for the quarter reached $628.34M , beating expectations by +2.83%.
Earnings released on 11 May 2022
EPS came in at $4.67 surpassing the estimated $3.38 by +38.17%, while revenue for the quarter reached $650.22M , beating expectations by +3.81%.
Dividend declared on 24 Mar 2022
A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 28 Mar 2022.
Earnings released on 9 Feb 2022
EPS came in at $2.09 surpassing the estimated $1.89 by +10.58%, while revenue for the quarter reached $617.72M , missing expectations by -2.09%.
Earnings released on 10 Nov 2021
EPS came in at $2.78 surpassing the estimated $2.06 by +34.95%, while revenue for the quarter reached $626.11M .
Earnings released on 18 Aug 2021
EPS came in at $1.90 surpassing the estimated $1.83 by +3.83%, while revenue for the quarter reached $631.26M .
Earnings released on 11 May 2021
EPS came in at $3.13 surpassing the estimated $2.97 by +5.39%, while revenue for the quarter reached $675.08M .
Dividend declared on 24 Mar 2021
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 26 Mar 2021.
Earnings released on 4 Feb 2021
EPS came in at $1.89 surpassing the estimated $0.55 by +243.64%, while revenue for the quarter reached $701.13M .
Earnings released on 3 Nov 2020
EPS came in at $2.38 surpassing the estimated $1.99 by +19.60%, while revenue for the quarter reached $703.35M .
HLBBF Stock Performance
Access detailed HLBBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.